Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083566 | 0.98 | TAS1R3 (0.42) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL5086064 | 0.97 | TAS1R3 (0.38) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL5083648 | 0.87 | DNPH1 (0.37) | ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL5082973 | 0.83 | ADORA1 (0.46) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5086082 | 0.83 | NPC1 (0.36) | ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL5083021 | 0.81 | ADORA1 (0.47) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5086004 | 0.81 | KDM4E (0.36) | ADORA2ACYP1A2CYP3A4CYP2D6NT5E | |
| SCHEMBL5083000 | 0.80 | ADORA1 (0.41) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5086442 | 0.78 | TAS1R3 (0.42) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL5086122 | 0.77 | TAS1R3 (0.39) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | ADORA1 1330/4885ADORA3 170/4885ADORA2A 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.